Saturday, November 21, 2026

Observations of the U.S. Preventive Services Task Force meeting

Last month, I wrote a Medscape commentary titled "Advice for the New USPSTF" that made several suggestions about how to get the Task Force's work back on track after an 18-month hiatus since its last meeting. I advised that the 8 new members receive a grounding in the USPSTF's rigorous methods for making recommendations, that the Agency for Healthcare Research and Quality (AHRQ) be supplied with resources and staff to support the work, that the Task Force set priorities for updating recommendations free from political interference, and that old and new members resist the temptation to "assign certain services stronger ratings than warranted by the evidence so that patients can more easily access them."

I didn't expect anyone in the leadership of the Department of Health and Human Services, much less Secretary Kennedy, to heed my advice. Still, it was discouraging to read Maggie Astor's New York Times story earlier this week, based on interviews with 15 former USPSTF members and AHRQ employees, outlining how this administration has systematically dismantled its evidence synthesis infrastructure and asserted political control over every aspect of its operations.

Historically, USPSTF meetings have been invitation-only and not open to the public. As much as I've written about the Task Force over the years, the last meeting I attended was in 2010, my last as an AHRQ medical officer. The afternoon prior to the Nov. 19-20 meeting, AHRQ announced that portions would be open to the public on Zoom. Since I had administrative time on Thursday morning, I decided to tune in.

It's important to emphasize that Task Force meetings, while critical to discussing and finalizing recommendations, represent the culmination of many hours of behind-the-scenes work that takes place during conference calls between meetings. I heard from one of the current USPSTF members that they continued much of this work despite not being allowed to meet from March 2025 until now. But it was immediately clear that there had been little interaction between the recently appointed members and the so-called "legacy" members selected previously through the traditional apolitical process.

Not only had the new members evidently skipped reading the methods manual, they seemed to have not been briefed at all on the 3 recommendations slated to be finalized: screening for cervical cancer, screening for unhealthy alcohol use, and counseling to prevent perinatal depression. (Normally this would be a discredit to the AHRQ staff, but remember, they have all been fired or forced to resign.) One new member complained that differences between the USPSTF's screening guidelines and those of medical groups are confusing to clinicians. As a practicing family physician, I empathize, but his proposed solution - having the Task Force instead adopt, wholesale, the other group's consensus guideline - showed a total misunderstanding of the purpose of the USPSTF. Medical groups have lots of reasons to make recommendations that go beyond the evidence; the Task Force is supposed to only recommend interventions that literature shows unequivocally improve outcomes for patients.

I give the legacy members credit for pushing back during this meeting. They criticized a political oversight process that had stripped out all references to race and sexual minorities from a statement when these characteristics were relevant to many scientific studies. When the AHRQ director (a molecular pathologist and lawyer whose official biography suggests hasn't practiced medicine since residency) pontificated that making decisions about patients based solely on their race is unethical, a Task Force member countered that this was a straw man, and no one in the room was advocating any such thing. Several members questioned AHRQ's unprecedented decision to invite intellectually and financially conflicted subspecialists to present on chronic kidney disease, colorectal cancer, and lung cancer. (To be clear, subspecialists have been involved in the development of USPSTF recommendations long before any were appointed to the Task Force, but evidence is typically presented by neutral systematic reviewers.)

The Times published a follow-up story with additional details worth reading (though oddly, it shows a stock photo of Secretary Kennedy, who did not attend). I suppose it could have been worse, but what I saw at this week's meeting did little to reassure me that the current incarnation of the USPSTF will be an asset to primary care, particularly after 3 more legacy members rotate off at the end of this year.

Sunday, November 15, 2026

Optimal blood pressure targets: RCTs vs real-world data

New hypertension practice guidelines from the American Heart Association / American College of Cardiology (AHA/ACC) and Hypertension Canada are summarized in the October 2026 issue of American Family Physician. In contrast to a previous guideline that I co-authored from the American Academy of Family Physicians, both guidelines recommend treating to a systolic blood pressure (BP) target of less than 130 mm Hg.

A recent systematic review and meta-analysis compared intensive BP lowering to standard BP targets (less than 140/90 mm Hg) in 27 randomized trials (N = 88,830) that followed patients for at least one year. Overall, an intensive treatment strategy reduced the relative risk of major cardiovascular events by 15% for each 10 mm Hg decrease in systolic BP. Individuals with and without chronic kidney disease experienced 4.3 and 2.7 fewer events per 1000 person-years, translating to numbers needed to treat of 46 and 74 to prevent one cardiovascular event over 5 years. On the harms side, intensive BP lowering increased the risk of sustained declines in estimated glomerular filtration rate by 42% to 47% but did not affect the risk of kidney failure.

Since measurement and treatment protocols may differ substantially between the clinical trial environment and real-life primary care practice, researchers performed a retrospective cohort study​ in 2.3 million patients with hypertension seen at Veterans Health Administration outpatient practices in 2016 and 2017, with follow-up through March 2021. Dividing patients into groups based on 10 mm Hg increments of systolic BP, the study found that a systolic BP of 130 to 139 mm Hg was associated with the lowest all-cause mortality, followed by a systolic BP of 140 to 149 mm Hg, then a systolic BP of 120 to 129 mm Hg. This finding held regardless of cardiovascular disease history, though the mortality benefit was greater in persons with known cardiovascular disease.

The contradictory results of these studies suggest that despite the new guidelines, the optimal BP treatment target remains open to debate. In a 2025 editorial in AFP, Drs. Mark Ebell and David Slawson noted that specialist-authored guidelines generally recommend more intensive BP targets than primary care or multispecialty guidelines, and the BP measurement protocols used in the two largest randomized trials, SPRINT (Systolic Blood Pressure Intervention Trial) and BPROAD (Blood Pressure Control Target in Diabetes), are time-consuming and difficult to implement in routine practice. Treating to a systolic BP target of less than 130 mm Hg based on typical BP measurement protocols increases the risk of hypotension, adverse kidney events, and unnecessary polypharmacy. The authors concluded:

The decision to pursue a more intensive BP target should not be routine and, at best, should be a shared decision balancing benefits and harms. To avoid overtreatment, it is of paramount importance that patients who choose a BP target of less than 130/80 mm Hg always have their BP measured using the time-consuming SPRINT or BPROAD protocol.

**

This post first appeared on the AFP Community Blog.

Sunday, November 1, 2026

How are clinicians utilizing AI to answer medical questions?

At the turn of the century, Dr. John Ely and colleagues observed 103 family physicians for two half-day clinical sessions and analyzed 1,101 questions that arose during patient care​. Physicians spent an average of less than 2 minutes seeking answers to 399 (36%) clinical questions. Nearly all information sources were colleagues or printed materials; only 10 times did physicians consult a computer. In contrast, a 2022 study​ of 31 family and other generalist physicians found that 93% of clinical questions were answerable with online resources, mostly using summaries of pre-appraised and synthesized evidence. However, for 32% of questions it took more than 5 minutes to retrieve an answer, too slow to be useful at the point of care.

Clinicians can use artificial intelligence platforms such as Open Evidence (OE) to answer questions more efficiently. (Full disclosure: OE partners with the American Academy of Family Physicians to surface content from American Family Physician in responses to queries.) A 2025 retrospective study​ evaluated OE’s performance in providing evidence-based recommendations for 5 primary care patients with common chronic conditions (hypertension, hyperlipidemia, type 2 diabetes, depression, and obesity). Physician reviewers rated OE’s recommendations highly for clarity, relevance, and evidence support, but noted that these generally reinforced physician plans rather than modifying them. Earlier this year, OE added strength of evidence ratings to answers​, ranging from A (strong) to D (minimal).

In a descriptive study in JAMA​, Dr. Vishal Patel and colleagues reported the content of more than 270 million queries submitted to OE by more than 950,000 US clinicians (including 556,200 physicians) from January 2024 to June 2026. On average, nurse practitioners and physician assistants submitted more queries per month than physicians. Residents, fellows, and early career physicians used OE more frequently than physicians with more than 10 years in practice.

Across medical specialties, hematologist-oncologists, internists, and family physicians submitted the most queries relative to their proportions in the workforce. Large numbers of queries were directed outside of a physician’s specialty; for example, 70% of queries from surgeons involved nonsurgical topics. Although the majority of queries (51.9%) were tied to a specific patient care decision, other purposes included general clinical knowledge, retrieval of research studies or guidelines, administrative tasks (eg, insurance appeal letters, patient education), teaching materials, and professional development.

An accompanying editorial​ highlighted some of the study’s limitations and directions for future research:

Patel and colleagues did not evaluate the quality of generated responses to queries, clinicians’ assessments of their accuracy or usefulness, or how the information was applied to or affected patient care. The study also could not distinguish use during clinical encounters from “precharting” preparation or general educational efforts. Returning users suggest perceived value, but engagement is not evidence of patient benefit.

It has never been easier for clinicians to answer questions that come up at the point of care. As always, the relevance and validity of retrieved information​ determines its usefulness, potential to change practice, and likelihood of improving patient-oriented outcomes.

**

This post first appeared on the AFP Community Blog.